Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation

Qu,Geping; Liu,Changting; Sun,Baojun; Zhou,Changxi; Zhang,Zhijian; Wang,Peng

doi:10.3892/or.2014.3178

Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation

Authors:
- Geping Qu
- Changting Liu
- Baojun Sun
- Changxi Zhou
- Zhijian Zhang
- Peng Wang
View Affiliations

Affiliations: Nanlou Respiratory Diseases Department, The Chinese People's Liberation Army (PLA) General Hospital, Beijing 100853, P.R. China
Published online on: May 15, 2014 https://doi.org/10.3892/or.2014.3178
Pages: 341-347

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the EGFR tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown marked effects against EGFR-mutated lung cancer, patients acquire resistance by various mechanisms, including the EGFR T790M mutation and Met induction, consequently suffering relapse. Thus, novel agents to overcome EGFR-TKI resistance are urgently needed. We aimed to investigate the inhibitory effects of a combination of BIBW2992 (irreversible EGFR inhibitor)/ARQ 197 (MET inhibitor) on the human lung adenocarcinoma cell line H1975. H1975 cells (harboring a T790M mutation in EGFR) were treated with erlotinib, BIBW2992 or ARQ 197 separately or with combinations of erlotinib/ARQ 197 or BIBW2992/ARQ 197. Cell growth, apoptosis and cell cycle distribution were evaluated by MTT assay, Annexin V/propidium iodide (PI) double staining and flow cytometry, respectively. EGFR, MET, AKT, ERK and the respective phosphorylated counterparts were detected by western blot analysis. Pathway-specific knockdown of MET and/or EGFR kinase signaling was achieved by siRNA interference. H1975 cells displayed EGFR and MET activation, and were resistant to erlotinib. The BIBW2992/ARQ 197 combination significantly inhibited growth, induced cell cycle arrest and apoptosis, and altered the phosphorylation of EGFR, MET, AKT and ERK1/2 in the H1975 cells. Phosphorylation of AKT and ERK1/2, downstream effectors of the EGFR and MET pathways, was not affected by the other tested treatments. Finally, knockdown of MET and/or EGFR in the H1975 cells confirmed the enhanced downstream inhibition of both MET and EGFR pathways. Combination of an irreversible EGFR inhibitor and MET inhibitor is effective in controlling H1975 cells with acquired resistance to erlotinib, by a mechanism involving the downregulation of PI3K/AKT and MEK/ERK signaling pathways.

View Figures

View References

1	Vincent MD, Kuruvilla MS, Leighl NB and Kamel-Reid S: Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol. 19:S33–S44. 2012. View Article : Google Scholar : PubMed/NCBI
2	Capelletto E and Novello S: Emerging new agents for the management of patients with non-small cell lung cancer. Drugs. 72(Suppl 1): 37–52. 2012. View Article : Google Scholar : PubMed/NCBI
3	Suda K, Mizuuchi H, Maehara Y and Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation - diversity, ductility, and destiny. Cancer Metastasis Rev. 31:807–814. 2012. View Article : Google Scholar
4	Liu Y, Shi QF, Ye YC, Tashiro S, Onodera S and Ikejima T: Activated O₂^•− and H₂O₂ mediated cell survival in SU11274-treated non-small-cell lung cancer A549 cells via c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 pathways. J Pharmacol Sci. 119:150–159. 2012.
5	Ayoola A, Barochia A, Belani K and Belani CP: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 30:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
6	Xu L, Kikuchi E, Xu C, et al: Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 72:3302–3311. 2012. View Article : Google Scholar : PubMed/NCBI
7	Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
8	Takezawa K, Okamoto I, Tanizaki J, et al: Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 9:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
9	Dulak AM, Gubish CT, Stabile LP, Henry C and Siegfried JM: HGF-independent potentiation of EGFR action by c-Met. Oncogene. 30:3625–3635. 2011. View Article : Google Scholar : PubMed/NCBI
10	Nakachi I, Naoki K, Soejima K, et al: The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res. 8:1142–1151. 2010. View Article : Google Scholar
11	Liu X, Newton RC and Scherle PA: Development of c-MET pathway inhibitors. Expert Opin Investig Drugs. 20:1225–1241. 2011. View Article : Google Scholar : PubMed/NCBI
12	Nakagawa T, Takeuchi S, Yamada T, et al: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11:2149–2157. 2012. View Article : Google Scholar : PubMed/NCBI
13	Comoglio PM, Giordano S and Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7:504–516. 2008. View Article : Google Scholar : PubMed/NCBI
14	Brambilla E and Gazdar A: Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J. 33:1485–1497. 2009. View Article : Google Scholar : PubMed/NCBI
15	Suda K, Tomizawa K, Osada H, et al: Conversion from the ‘oncogene addiction’ to ‘drug addiction’ by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer. 76:292–299. 2012.
16	Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:3472–3475. 2002. View Article : Google Scholar
17	Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 15:2552–2558. 2009. View Article : Google Scholar : PubMed/NCBI
19	Guo A, Villen J, Kornhauser J, et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
20	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar
21	Tang Z, Du R, Jiang S, et al: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 99:911–922. 2008. View Article : Google Scholar : PubMed/NCBI
22	Suda K, Murakami I, Katayama T, et al: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 16:5489–5498. 2010.PubMed/NCBI
23	Bonanno L, Jirillo A and Favaretto A: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr Drug Targets. 12:922–933. 2011. View Article : Google Scholar : PubMed/NCBI
24	Bowles DW, Weickhardt A and Jimeno A: Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today. 49:523–535. 2013. View Article : Google Scholar : PubMed/NCBI
25	Nelson V, Ziehr J, Agulnik M and Johnson M: Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 6:135–143. 2013.PubMed/NCBI
26	Chen X, Zhu Q, Zhu L, et al: Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 81:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wang W, Li Q, Takeuchi S, et al: Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 18:1663–1671. 2012. View Article : Google Scholar
28	Koizumi H, Yamada T, Takeuchi S, et al: Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI